• Contact: +91-9643310025, 9643312749
  • Generic selectors
    Exact matches only
    Search in title
    Search in content
    Search in posts
    Search in pages
    Filter by Categories
    Annual brand plans
    Autoimmune diseases
    Conference support
    Corporate strategy and R & D consulting
    KOL support
    MSL training
    Orphan Diseases
    Pre-& post launch activities
    Sales & marketing
    Sales force training

Gilles de la Tourette’s syndrome Pipeline Dashboard, H1 2018

Scope of report

  • The report provides a snapshot of the global therapeutic landscape of Gilles de la Tourette’s syndrome.
  • The report assesses Gilles de la Tourette’s syndrome pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • The report reviews Gilles de la Tourette’s syndrome pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The report covers pipeline products based on various stages of development for Gilles de la Tourette’s syndrome ranging from discovery to pre-registration and undisclosed stages.

Companies Covered:

Otsuka Pharmaceutical, Carlsson Research AB, Pfizer, Afecta Pharmaceuticals, Northwestern University, AstraZeneca, Synchroneuron, Abide Therapeutics, Therapix Biosciences, Schering-Plough, LifeHealth Limited, Neurocrine Biosciences, Janssen L.P., Boehringer Ingelheim, Reviva Pharmaceuticals, Auspex Pharmaceuticals, Allergan

Key Drugs:

Aripiprazole, Seridopidine, PF 3654746, Vigabatrin, AFX 221, CPP 115, AZD 5213, Acamprosate, ABX 1431, THX TS01, Ecopipam, Tetrabenazine, Valbenazine, Risperidone, Pramipexole, Botulinum toxin A, Vatiquinone, RP 5063, Deutetrabenazine, Botulinum toxin A injectable

Publisher: Pharmintel

Format: Microsoft Excel
Sheets: 8

  • Single Use:  $300
  • Site License: $500
  • Global License: $800

Report Inquiry

Leave a Reply

Your email address will not be published. Required fields are marked *

+91 9643310025, 9643312749
© 2024 Pharmintel